Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Piroxicam. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 known ✓ | P23219 | 5/20 | 0.98 |
| ▸ | PTGS2 known ✓ | P35354 | 3/20 | 0.98 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.98 |
| ▸ | USP2 | O75604 | 3/20 | 0.98 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.98 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.98 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.98 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.98 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.98 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.98 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.98 |
| ▸ | BLM | P54132 | 1/20 | 0.98 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.98 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.98 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.95 |
| ▸ | GAA | P10253 | 1/20 | 0.68 |
| ▸ | LMNA | P02545 | 2/20 | 0.66 |
| ▸ | KDR | P35968 | 1/20 | 0.66 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.64 |
| ▸ | POLB | P06746 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Piroxicam SCHEMBL2680486 | 0.99 | PTGS1 (1.00) | PTGS1KDM4EUSP2PTGS2CYP2C9 | |
| Piroxicam SCHEMBL28536166 | 0.99 | PTGS1 (1.00) | PTGS1KDM4EUSP2PTGS2CYP2C9 | |
| Piroxicam SCHEMBL29396075 | 0.99 | PTGS1 (1.00) | PTGS1KDM4EUSP2PTGS2CYP2C9 | |
| Piroxicam SCHEMBL13462 | 0.99 | PTGS1 (1.00) | PTGS1KDM4EUSP2PTGS2CYP2C9 | |
| Piroxicam SCHEMBL29352427 | 0.99 | PTGS1 (1.00) | PTGS1KDM4EUSP2PTGS2CYP2C9 | |
| Piroxicam SCHEMBL15741898 | 0.99 | PTGS1 (1.00) | PTGS1KDM4EUSP2PTGS2CYP2C9 | |
| Piroxicam SCHEMBL6759456 | 0.98 | KDM4E (1.00) | PTGS1KDM4EUSP2PTGS2CYP2C9 | |
| Piroxicam SCHEMBL6942519 | 0.98 | PTGS1 (0.98) | PTGS1KDM4EUSP2PTGS2CYP2C9 | |
| Piroxicam SCHEMBL8908556 | 0.98 | PTGS1 (0.98) | PTGS1KDM4EUSP2PTGS2CYP2C9 | |
| Piroxicam SCHEMBL27394226 | 0.98 | PTGS1 (0.98) | PTGS1KDM4EUSP2PTGS2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008069546-A1 | ORAL ADMINISTRATIVE PREPARATION FOR TREATING CARDIOVASCULAR SYSTEM DISEASE | BORYUNG PHARMACEUTICAL CO., LTD (KR) | 2008-06-12 | — | — | WO | claimed |
| CN-1047077-C | Stable, painless piroxicam potassium injectable composition | KIM YOUNG SUL (KR) | 1999-12-08 | — | — | CN | claimed |
| CN-1105241-A | Stable, painless piroxicam potassium injectable composition | KIM YOUNG SUL (KR) | 1995-07-19 | — | — | CN | claimed |
| US-5420124-A | Stable, painless piroxicam potassium injectable composition | KIM, WON KYU (KR) | 1995-05-30 | — | — | US | claimed |
| CN-113527282-B | 1, 2-benzothiazine heterocyclic derivative and preparation method and application thereof | 齐鲁医药学院 | 2023-02-07 | — | — | CN | disclosed |
| CN-113527282-A | 1, 2-benzothiazine heterocyclic derivative and preparation method and application thereof | 齐鲁医药学院 | 2021-10-22 | — | — | CN | disclosed |
| US-10940205-B2 | Compositions of pharmaceutical actives containing diethylene glycol monoethyl ether or other alkyl derivatives | THEMIS MEDICARE LIMITED (IN) | 2021-03-09 | — | — | US | disclosed |
| US-20180071390-A1 | COMPOSITIONS OF PHARMACEUTICAL ACTIVES CONTAINING DIETHYLENE GLYCOL MONOETHYL ETHER OR OTHER ALKYL DERIVATIVES | THEMIS MEDICARE LIMITED (IN) | 2018-03-15 | — | — | US | disclosed |
| US-9827315-B2 | Compositions of pharmaceutical actives containing diethylene glycol monoethyl ether or other alkyl derivatives | THEMIS MEDICARE LIMITED (IN) | 2017-11-28 | — | — | US | disclosed |
| US-9375483-B2 | Stable liquid pharmaceutical composition containing piroxicam or its pharmaceutically acceptable salt and hyaluronic acid or its pharmaceutically acceptable salt and the manufacturing method thereof | DONG-A ST CO., LTD. (KR) | 2016-06-28 | — | — | US | disclosed |
| US-20160106774-A1 | LIQUID PHARMACEUTICAL COMPOSITION CONTAINING PIROXICAM AND HYALURONIC ACID FOR THE TREATMENT OF OSTEOARTHRITIS | DONG-A ST CO., LTD. (KR) | 2016-04-21 | — | — | US | disclosed |
| EP-3007702-A1 | LIQUID PHARMACEUTICAL COMPOSITION CONTAINING PIROXICAM AND HYALURONIC ACID FOR THE TREATMENT OF OSTEOARTHRITIS | Dong-A ST Co., Ltd. (KR) | 2016-04-20 | — | — | EP | disclosed |
| CN-1047077-C | Stable, painless piroxicam potassium injectable composition | KIM YOUNG SUL (KR) | 1999-12-08 | — | — | CN | disclosed |
| CN-1047077-C | Stable, painless piroxicam potassium injectable composition | KIM YOUNG SUL (KR) | 1999-12-08 | — | — | CN | disclosed |
| CN-1105241-A | Stable, painless piroxicam potassium injectable composition | KIM YOUNG SUL (KR) | 1995-07-19 | — | — | CN | disclosed |
| CN-1105241-A | Stable, painless piroxicam potassium injectable composition | KIM YOUNG SUL (KR) | 1995-07-19 | — | — | CN | disclosed |
| CN-1105241-A | Stable, painless piroxicam potassium injectable composition | KIM YOUNG SUL (KR) | 1995-07-19 | — | — | CN | disclosed |
| US-5420124-A | Stable, painless piroxicam potassium injectable composition | KIM, WON KYU (KR) | 1995-05-30 | — | — | US | disclosed |
| US-5420124-A | Stable, painless piroxicam potassium injectable composition | KIM, WON KYU (KR) | 1995-05-30 | — | — | US | disclosed |
| US-5420124-A | Stable, painless piroxicam potassium injectable composition | KIM, WON KYU (KR) | 1995-05-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180071390-A1 | COMPOSITIONS OF PHARMACEUTICAL ACTIVES CONTAINING DIETHYLENE GLYCOL MONOETHYL ETHER OR OTHER ALKYL DERIVATIVES | DSG1, DEGS1, PLA2G2E | PTGS1 201/4885PTGS2 369/4885KDM4E 223/4885 |
| US-10940205-B2 | Compositions of pharmaceutical actives containing diethylene glycol monoethyl ether or other alkyl derivatives | DSG1, DEGS1, PLA2G2E | PTGS1 201/4885PTGS2 369/4885KDM4E 223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.